a public good project by the
Synthesis
Company
of California

© 2026

Pierre‐Marie Girard | doi.page

0 works0 citations0 h-index

Pierre‐Marie Girard

Publications by Year

Research Areas

HIV/AIDS drug development and treatment, HIV Research and Treatment, HIV/AIDS Research and Interventions, Hepatitis C virus research, Hepatitis B Virus Studies

Most-Cited Works

→ Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection(2020)443 cited
→ Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials(2018)373 cited
→ Fanconi syndrome and renal failure induced by tenofovir: A first case report(2002)354 cited
→ Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies(2018)342 cited
→ High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics(2015)264 cited
→ Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial(2002)244 cited

→ Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients(2004)211 cited

→ Campylobacter Bacteremia: Clinical Features and Factors Associated with Fatal Outcome(2008)203 cited

→ Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials(2019)203 cited

→ Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV(2013)199 cited